This application is for a cooperative agreement to continue the Cancer Partnership as a triad with participation from Vanderbilt-lngram Cancer Center (VICC), Meharry Medical College (MMC) and Tennessee State University (TSU). Program administrators of the National Cancer Institute (NCI) of the National Institutes of Health (NIH) will be part of the Program Steering Committee for this Program and will be consulted and kept apprised of progress. As such. Dr. Nelson Aguila, Diversity Training Branch in the Center to Reduce Cancer Health Disparities at the NCI, has provided the requisite approval for the submission of this triad application. A copy of this approval letter is included in Section 14 "Letters of Support". The Partnership was developed in 1999 and continues with the goal of strengthening cancer research capabilities of MMC and TSU as well as providing exposure and resources for faculty at VICC focusing on cancer disparities research, mentoring junior faculty and training the next generation of minority students and postdoctoral fellows. The administrative leadership teams of the three institutions are jointly responsible for the overall management, coordination and support of the components in the Partnership. We have a longstanding and close working relationship with the administrative teams of our Partner organizations, resulting in numerous supportive interactions. The internal activities of the Partnership will be accomplished by the respective Administrative Cores in close collaboration with the Internal Advisory Committee and Program Steering Committees of the Partnership. Figure 1 represents the organizational structure of the parties involved in the Partnership. The figure also depicts direct lines of communication between the Administrative Cores based at the VICC, MMC and TSU and the other participating components.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163072-03
Application #
8541776
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
3
Fiscal Year
2013
Total Cost
$86,906
Indirect Cost
$36,446
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Nichols, Erin E; Richmond, Ann; Daniels, Anthony B (2016) Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma. Semin Ophthalmol 31:304-9
Nichols, Erin E; Richmond, Ann; Daniels, Anthony B (2016) Disparities in Uveal Melanoma: Patient Characteristics. Semin Ophthalmol 31:296-303
Moore, Kelly L; Fankhauser, Melissa K; Hull, Pamela C (2016) Tennessee's 3-Star Report: Using Available Data Systems to Reduce Missed Opportunities to Vaccinate Preteens. Biomed Inform Insights 8:15-21
Wanjala, Jackie; Taylor, Barry S; Chapinski, Caren et al. (2015) Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Mol Cancer Ther 14:278-88
Brown, Shyretha; Whalen, Margaret (2015) Tributyltin alters secretion of interleukin 1 beta from human immune cells. J Appl Toxicol 35:895-908
Vaiopoulou, Anna; Gazouli, Maria; Papadopoulou, Aggeliki et al. (2015) Serum protein profiling of adults and children with Crohn disease. J Pediatr Gastroenterol Nutr 60:42-7
Sanderson, Maureen; O'Hara, Heather; Foderingham, Nia et al. (2015) Type 2 diabetes and mammographic breast density among underserved women. Cancer Causes Control 26:303-9
Chen, Zhenbang; Lu, Wenfu (2015) Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications. Int J Mol Sci 16:4560-80
Bates, Andreia L; Pickup, Michael W; Hallett, Miranda A et al. (2015) Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases. J Pathol 235:773-83
Lu, Wenfu; Liu, Shenji; Li, Bo et al. (2015) SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget 6:771-88

Showing the most recent 10 out of 72 publications